UBS Group
ALDX icon

UBS Group’s Aldeyra Therapeutics ALDX Stock Holding History

UBS Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$908K Buy
537,569
+441,892
+462% +$1.94M ﹤0.01% 5625
2025
Q4 		$496K Sell
95,677
-105,062
-52% -$540K ﹤0.01% 6093
2025
Q3 		$1.05M Buy
200,739
+93,486
+87% +$488K ﹤0.01% 5537
2025
Q2 		$411K Buy
107,253
+12,783
+14% +$33K ﹤0.01% 6175
2025
Q1 		$543K Buy
94,470
+195
+0.2% +$1.15K ﹤0.01% 5791
2024
Q4 		$470K Buy
94,275
+67,746
+255% +$348K ﹤0.01% 5892
2024
Q3 		$143K Sell
26,529
-21,497
-45% -$102K ﹤0.01% 6103
2024
Q2 		$159K Sell
48,026
-290
-0.6% -$1.14K ﹤0.01% 5824
2024
Q1 		$158K Sell
48,316
-4,761
-9% -$15.7K ﹤0.01% 6005
2023
Q4 		$186K Sell
53,077
-21,518
-29% -$66.4K ﹤0.01% 5817
2023
Q3 		$498K Sell
74,595
-14,634
-16% -$109K ﹤0.01% 4656
2023
Q2 		$749K Buy
89,229
+82,821
+1,292% +$816K ﹤0.01% 4490
2023
Q1 		$63.6K Buy
6,408
+4,608
+256% +$32.6K ﹤0.01% 6264
2022
Q4 		$12.5K Sell
1,800
-24,003
-93% -$137K ﹤0.01% 8256
2022
Q3 		$138K Sell
25,803
-734,694
-97% -$4.41M ﹤0.01% 5423
2022
Q2 		$3.04M Sell
760,497
-199,896
-21% -$687K ﹤0.01% 2788
2022
Q1 		$4.27M Buy
960,393
+776,593
+423% +$3.09M ﹤0.01% 2686
2021
Q4 		$735K Buy
183,800
+46,617
+34% +$356K ﹤0.01% 4657
2021
Q3 		$1.21M Buy
137,183
+122,307
+822% +$1.12M ﹤0.01% 4028
2021
Q2 		$168K Sell
14,876
-34,031
-70% -$409K ﹤0.01% 5484
2021
Q1 		$581K Sell
48,907
-53,473
-52% -$616K ﹤0.01% 4753
2020
Q4 		$702K Sell
102,380
-3,661
-3% -$25.7K ﹤0.01% 4306
2020
Q3 		$785K Buy
106,041
+102,823
+3,195% +$664K ﹤0.01% 3818
2020
Q2 		$14K Sell
3,218
-11,936
-79% -$43.6K ﹤0.01% 6779
2020
Q1 		$37K Sell
15,154
-26,517
-64% -$119K ﹤0.01% 6060
2019
Q4 		$242K Buy
41,671
+16,580
+66% +$95.8K ﹤0.01% 5462
2019
Q3 		$132K Buy
25,091
+15,815
+170% +$85.1K ﹤0.01% 5582
2019
Q2 		$56K Sell
9,276
-3,581
-28% -$26.9K ﹤0.01% 5814
2019
Q1 		$116K Buy
12,857
+140
+1% +$1.19K ﹤0.01% 4958
2018
Q4 		$106K Buy
12,717
+1,452
+13% +$14.9K ﹤0.01% 5488
2018
Q3 		$155K Buy
11,265
+4,109
+57% +$33.3K ﹤0.01% 5241
2018
Q2 		$57K Buy
7,156
+715
+11% +$5.7K ﹤0.01% 5874
2018
Q1 		$48K Buy
6,441
+4,516
+235% +$34.3K ﹤0.01% 5734
2017
Q4 		$13K Buy
1,925
+661
+52% +$4.35K ﹤0.01% 6851
2017
Q3 		$9K Buy
1,264
+156
+14% +$815 ﹤0.01% 6933
2017
Q2 		$5K Sell
1,108
-721
-39% -$3.31K ﹤0.01% 7100
2017
Q1 		$9K Buy
+1,829
New +$9.42K ﹤0.01% 6658
2016
Q2 		– Sell
-2,784
Closed -$12K – 7683
2016
Q1 		$12K Buy
2,784
+2,715
+3,935% +$13K ﹤0.01% 6532
2015
Q4 		$0 Sell
69
-1,520
-96% -$10.2K ﹤0.01% 8307
2015
Q3 		$9K Sell
1,589
-333
-17% -$2.6K ﹤0.01% 7318
2015
Q2 		$15K Buy
1,922
+1,713
+820% +$14.8K ﹤0.01% 7126
2015
Q1 		$2K Buy
+209
New +$2.13K ﹤0.01% 8423

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group's ALDX Position: Q1 2026 in Review

UBS Group increased its Aldeyra Therapeutics (ALDX) stake by 462% in Q1 2026, buying an estimated $1.94M and bringing the position to 537,569 shares worth $908K. The position accounts for ﹤0.01% of the portfolio, ranked #5625.

UBS Group first reported a position in ALDX in Q1 2015 and has held it in 42 quarters since. The position peaked at $4.27M in Q1 2022. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • UBS Group held 537,569 shares of Aldeyra Therapeutics worth $908K as of Q1 2026.
  • UBS Group bought 441,892 Aldeyra Therapeutics shares in Q1 2026, an estimated $1.94M.
  • Aldeyra Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5625 holding.
  • UBS Group first reported a position in Aldeyra Therapeutics in Q1 2015 and has held it in 42 quarters since.
  • UBS Group's Aldeyra Therapeutics position peaked at $4.27M in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.